ArticlePloS one2026
High prevalence of resistance to first-line drugs and multidrug resistance in patients with tuberculosis and type 2 diabetes mellitus at a referral hospital in Peru.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe coexistence of tuberculosis (TB) and type 2 diabetes mellitus (T2DM) poses an emerging public health challenge, especially in high-TB-burden settings such as Peru. This comorbidity has been associated to unfavorable clinical outcomes and a higher frequency of drug-resistant TB.
objectiveTo estimate the prevalence of resistance to first-line antituberculosis drugs and identify factors associated with multidrug resistance tuberculosis (MDR-TB) among patients with T2DM and pulmonary TB treated at a public hospital in Lima, Peru.
methodsA cross-sectional study was conducted using secondary data from 130 adults with T2DM and microbiologically confirmed pulmonary TB treated at a Peruvian hospital between 2015 and 2019. Drug susceptibility results were categorized as susceptible, monoresistant, polyresistant, or MDR-TB. Factors associated with MDR and resistance to at least one first-line drug were evaluated using Poisson regression models with robust variance.
resultsThe prevalence of resistance to at least one first-line drug was 34.6%, and the prevalence of MDR-TB was 21.5%. The most frequent resistances were to isoniazid (28.4%) and rifampicin (26.2%). In the multivariable analysis, age 40-49 years (aPR = 2.99; 95% CI: 1.00-8.97) and age 70-85 years (aPR = 4.13; 95% CI: 1.16-14.7) and were independently associated with MDR-TB. Furthermore, a diabetes duration of at least 5 years was associated with resistance to at least one drug (aPR ≈ 2.1).
conclusionA high prevalence of drug resistance, including MDR-TB was observed among patients with T2DM and pulmonary TB. Older age and longer duration of diabetes were associated with bacterial resistance in the adjusted analysis. These findings underscore the importance of considering diabetes-related clinical characteristics when evaluating drug resistance patterns in patients with tuberculosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.